Microbot Medical (MBOT) Receives Daily News Sentiment Rating of 0.19

News coverage about Microbot Medical (NASDAQ:MBOT) has been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern ranks the sentiment of news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Microbot Medical earned a coverage optimism score of 0.19 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 45.5703873695031 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Here are some of the news headlines that may have impacted Accern Sentiment’s rankings:

Microbot Medical (NASDAQ:MBOT) traded down $0.02 during trading on Wednesday, reaching $1.02. 486,600 shares of the company’s stock traded hands, compared to its average volume of 887,598. Microbot Medical has a 1-year low of $1.00 and a 1-year high of $9.94.

In other Microbot Medical news, Director Moshe Shoham sold 33,700 shares of the business’s stock in a transaction on Monday, October 9th. The shares were sold at an average price of $1.50, for a total value of $50,550.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Yoseph Bornstein sold 53,000 shares of the business’s stock in a transaction on Wednesday, October 4th. The stock was sold at an average price of $1.20, for a total transaction of $63,600.00. The disclosure for this sale can be found here. Insiders sold 458,234 shares of company stock valued at $557,599 over the last three months. 31.83% of the stock is currently owned by insiders.

ILLEGAL ACTIVITY NOTICE: “Microbot Medical (MBOT) Receives Daily News Sentiment Rating of 0.19” was reported by Community Financial News and is owned by of Community Financial News. If you are reading this story on another publication, it was illegally stolen and reposted in violation of international copyright and trademark law. The correct version of this story can be viewed at https://www.com-unik.info/2017/12/20/microbot-medical-mbot-receives-daily-news-sentiment-rating-of-0-19.html.

Microbot Medical Company Profile

Microbot Medical Inc, formerly StemCells, Inc, is a medical device company. The Company specializes in the researching, designing, developing and commercializing transformational micro-robotic medical technologies leveraging the artificial and natural lumens within the human body. It is engaged in developing its two product candidates: the Self Cleaning Shunt (SCS) for the treatment of hydrocephalus and normal pressure hydrocephalus (NPH), and TipCAT, a self-propelling, semi-disposable endoscope that the Company is developing for use in colonoscopy procedures.

Insider Buying and Selling by Quarter for Microbot Medical (NASDAQ:MBOT)

Receive News & Ratings for Microbot Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microbot Medical and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit